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Synaptic dysfunction is a well‑documented manifestation in animal models of Alzheimer’s disease pathology. In this context, numerous 
studies have documented reduction in the functionality of synapses in various models. In addition, recent research has shed more 
light on increased excitability and its link to seizures and seizure‑like activities in AD patients as well as in mouse models. These reports 
of hyperexcitability contradict the observed reduction in synaptic function and have been suggested to be as a result of the interplay 
between inhibitory and excitatory neuronal mechanism. The present study therefore investigates functional deficiency in the inhibitory 
system as complementary to the identified alterations in the glutamate excitatory pathway in AD. Since synaptic function deficit in AD is 
typically linked to progression/pathology of the disease, it is important to determine whether the deficits in the GABAergic system are 
functional and can be directly linked to the pattern of the disruption documented in the glutamate system. To build on previous research 
in this field, experiments were designed to determine if previously documented synaptic dysfunction in AD models is concomitantly 
observed with excitation/inhibition imbalance as suggested by observation of seizure and seizure‑like pathology in such models. We 
report changes in synaptic function in aged APPPS1 mice not observable in the younger cohort. These changes in synaptic function 
are furthermore accompanied by alteration in the GABAergic neurotransmission. Thus, age‑dependent alteration in the inhibitory/
excitatory balance might underpin the symptomatic changes observed with the progression of Alzheimer’s disease pathology including 
sleep disturbance and epileptic events. 
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INTRODUCTION
Dual mutant mice models carrying various known 
mutations in the amyloid processing protein and the 
presinilin genes are widely used in the study of the 
pathology of Alzheimer’s disease (AD) (Jankowsky et al. 
2001). These models have been shown to mimic various of 
the AD related clinical pathology such as amyloid beta (Aβ) 
plaque load accumulation, deficits in synaptic function 
and structure, as well as deficits in learning and memory 
(Jankowsky et al. 2001, Trinchese et al. 2004, Radde et al. 
2006, Huang et al. 2016). 
Deficits in memory and changes in behavior remain the 
first clinical indications of AD (Alzheimer’s‑Association 
2015). The changes in cognitive functioning are however 
considered a result of accrued pathology. On the one 
hand empirical evidence exists showing that increased 
concentration of Aβ is directly linked to synaptic pathology 
observed in AD mouse models, even in the absence of 
plaque pathology (Lue et al. 1999, Zhang et al. 2011). On the 
other hand, studies have also documented changes in long 
and short term plasticity to be restricted to a later age in 
AD models when plaque pathology is clearly established 
(Trinchese et al. 2004, Gengler et al. 2010, Huang et al. 2016).
In addition to alterations in synaptic functioning, 
mouse models display increased aberrant network activity 
which has previously been linked to an imbalance in the 
excitation/inhibition ratio in such models (Palop and 
Mucke 2009, 2010, Hazra et al. 2013, 2016). Transgenic 
mice of the APP/PS1 models overexpress Swedish family 
mutated forms of the human amyloid precursor protein 
(APPswe) and various mutation in Presenilin1 result in 
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age‑dependent and region‑specific amyloid deposition 
(Jankowsky et al. 2001, Fitzjohn et al. 2010, Huang et al. 
2016). APP/PS1 mice spontaneously show seizures, which 
are believed to be associated to an imbalance in the 
excitatory/inhibitory function (i.e. altered glutamatergic 
and/or gamma‑aminobutyric acid [GABAergic pathways]) 
in the central nervous system in the pathology of AD 
(Howell et al. 2000, Ramos et al. 2006, Shankar et al. 2007, Li 
et al. 2011, Hazra et al. 2013). 
In the laboratory, long‑term potentiation (LTP) is a well‑
‑established electrophysiological phenomenon used in the 
detection of alterations or impairments in the molecular 
mechanism of learning and memory. LTP induction and 
sustenance are physiological synaptic events that are 
considered to be crucial for the proper functioning of 
the brain, i.e. memory formation (Shors and Matzel 1997, 
Malenka and Nicoll 1999, Bliim et al. 2016). Furthermore, 
the fact that LTP deficit is a common theme observed 
in AD mouse models strengthens the link between LTP 
and memory deficits observed in both clinical and/or 
preclinical research (Gengler et al. 2010, Sheng et al. 2012, 
Webster et al. 2014, Viana da Silva et al. 2016). 
The present paper uses the APP/PS1 mouse model of AD 
pathology to investigate the relationship between synaptic 
function, LTP, and GABAergic function and pathway 
signaling (Radde et al. 2006). To this end, the ability to 
induce LTP was assessed in an in vitro paradigm that gives 
insight into the ability of the hippocampus to strengthen 
synaptic association required for acquiring new memory 
and processing old memory alike (Lynch 2004, Bliim et 
al. 2016). Furthermore, the experiments were conducted 
at two time points in order to determine excitability 
threshold, short‑term plasticity as well as LTP induction 
in slices obtained from APP/PS1 mice in relation to plaque 
deposit as a function of age/disease progression. Lastly, 
alterations in GABA pathway functioning and related gene 
expression in the prefrontal cortex and hippocampus 
were assessed using microarray technology (Chebib and 
Johnston 1999, Johnston 2013).
METHODS
Animals: APP/PS1 mice 
This study is based on the well‑characterized, previously 
reported and published APP/PS1 mouse with the amyloid 
precursor protein APP Swedish mutation (KM670/671NL) 
and the aggressive mutation in the Presenilin1 (PS1‑L166P) 
on a C57BL/6 background (Radde et al. 2006). Mice were 
provided with standard laboratory rodent food and tap 
water ad libitum, while every effort was made to minimize 
pain in animal use and disturbances in animal well‑being. 
All protocols have been carried out in accordance 
with guidelines of the Association for Assessment and 
Accreditation of Laboratory Animal Care International 
(AAALAC), and of the European Communities Council 
Directive of 24 November 1986 (86/609/EEC) and were 
approved by Janssen Pharmaceutica Ethical Committee.
To examine the effects of age, two time points 
(‘ages’) were determined for the experimental design. 
These include a previously reported initial time point 
of 1.5 month of age, which is before the appearance of 
plaques in the APP/PS1 mouse model, while the second 
time point was chosen at 8 months of age when the plaque 
load is already clearly established in this mouse strain 
(Radde et al. 2006). 
Electrophysiology: Synaptic function and long‑term 
potentiation (LTP)
Mice were euthanized with carbon dioxide, decapitated, 
and whole brains were quickly removed and placed in ice 
cold artificial cerebrospinal fluid (aCSF). Slices were made 
from obtained brain samples using a vibratome (Leica 
Microsystems, Germany) while submerged in a chamber 
filled with ice‑cold cutting solution containing (in mM) 
125 NaCl, 2.5 KCl, 2 CaCl2, 2.5 MgCl2, 1.25 KH2PO4, 25 NaHCO3, 
25 glucose, saturated with 95% O2/5% CO2 (pH 7.2~7.3 and 
325 mOsm/kg). Hippocampi were horizontally cut at 
300 μM trimmed of cortical tissue and allowed to recover 
in oxygenated ACSF solution at room temperature for at 
least 1 hour. Hippocampal slices were transferred onto 
a MEA chip obtained from Qwane Bioscience® on the 200/30 
MEA system and continuously perfused at 1.5ml/min 
with oxygenated aCSF (in mM) 125 NaCl, 2.5 KCl, 2 CaCl2, 
1 MgCl2, 1.25 KH2PO4, 25 NaHCO3, 25 glucose, saturated 
with 95% O2/5% CO2 (pH 7.2~7.3 and 325 mOsm/kg) at 31°C. 
Stimulating electrode was placed in the Shaffer collateral 
and recording electrode(s) were positioned in the Cornu 
Ammonus 1 (CA1) area of the hippocampus.
Threshold for maximum response in the slices were 
determined by measuring the peak to peak response 
obtained with increases in stimulation strength (from 1 to 
150 µA or 200 µA) before conducting the LTP experiment in 
each slice (Xiong et al. 2013). Responses to IO curve obtained 
are compared between APP/PS1 and littermate mice. 
To determine short‑term plasticity paired pulse ratio 
(PPR) experiment were carried out with changes in the 
frequency used between pulses. The interval between the 
paired pulse range from 0.02 s to 20 s (frequencies ranging 
from 50 to 0.05 Hz) and are reported as the ratio of the peak 
to peak measurement of the second pulse divided by the 
first pulse (PPR).
Long‑term potentiation (LTP) was induced after 
15 min of baseline recording using a high frequency 
stimulation protocol containing 3 trains each composed 
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of 100 pulses at 100 Hz separated by 20 s. Continuous 
recording was maintained 60 min after the induction 
of LTP. All sweeps were normalized to the mean of the 
baseline sweeps. Analysis was done by measuring the 
slope of the recorded fEPSP response at baseline and after 
induction of LTP. Comparison was made between the 
baseline slope fEPSP and sweeps recorded immediately 
after LTP induction (10 min post HFS) or 50–60 min after 
LTP induction (50–60 min post LTP). 
Electrophysiology: GABA inhibitor application
To access the involvement of the GABAergic pathway 
in the pathology of AD, we conducted a set of experiments 
recording extracellular synaptic activities, namely field 
excitatory post synaptic potentials (fEPSP), using the new 
developed technology of Multi‑Electrode Array (MEA) 
(Howell et al. 2000, Ramos et al. 2006, Yoshiike et al. 
2008, Limon et al. 2012, Jo et al. 2014). These recording, 
in hippocampal brain slices, were used to determine if 
a differential effect is observed by the disinhibition of 
GABAergic signaling by comparing the effect of applying 
a GABA inhibitor on field potentials in APP/PS1 mice 
(Chebib and Johnston 1999, Johnston 2013). Similarly, the 
effect of application of benzodiazepine, a γ‑aminobutyric 
acid receptor A (GABAA) agonist, previously shown 
to result in a decrease in the established paired pulse 
depression ratio in earlier studies using rats is employed 
in this study to further characterize the functionality 
of the GABA pathway (Xie and Tietz 1991, Karnup and 
Stelzer 1999).
Horizontal brain slices were obtained and processed as 
above from APP/PS1 mice and littermate. Slices obtained 
were placed on a multi‑electrode array chip obtained from 
Qwane Biosciences®. Stimulating electrode was placed in 
the Shaffer collateral and recording electrode(s) were 
selected in the CA1 area of the hippocampus. Samples 
were obtained from cohorts of 1.5 months and 8 months 
old mice for each genotype. After 15 min of baseline 
recording in normal ACSF a cocktail of low concentrations 
inhibitors of the GABA receptor A type, Bicucculline 
(5 µM) and GABA receptor B type, 2‑Hydroxysaclofen 
(20 µM) were co‑applied for 15 min. Analysis was 
performed using 3 sweeps repeats at 5 min and 15 min 
of inhibitors application. All data points represent the 
calculated slope of the decay in the population spike. 
Comparison was made between application and baseline 
in order to determine the effect of inhibition application 
on the responses recorded. 
In a follow‑up experiment, hippocampal slices from 
8 months old APP/PS1 and littermate mice were obtained. 
Using the multi‑electrode array technology, as previously 
described, a stimulating electrode was placed in the 
Shaffer collateral and recording electrode(s) were selected 
in the CA1 area of the hippocampus. Baseline recording 
was established for 15 min before 30 min of application 
of 1 µM diazepam (a GABA receptor A type subunit 
agonist). Only slices with a paired pulse ratio greater 
than 0.5 and less than 1 (i.e. paired pulse depression) 
were selected and included in the analysis (King, Knox 
et al. 1985, Xie and Tietz 1991). Comparisons were made 
between genotype and application of the GABA agonist 
to determine the effect of agonist application and/or 
genotype on the GABAA specific function. Drugs used in 
this study were supplied by Tocris for 2‑hydroxysaclofen 
and bicucculline while diazepam was synthesized within 
Janssen Pharmaceutica.
Electrophysiological data were collected at a 10 kHz 
sampling frequency and 1100 amplifier gain. Triggered 
field Excitatory Postsynaptic Potentials (fEPSP) were 
recorded and processed with the use of MC_Rack®, Clampfit 
10.3® and MC_Data Tool software® (Multi Channel Systems, 
Germany). Analyzes were performed using GraphPad 
Prism 6®. Statistical analysis of all electrophysiological 
data was performed by using standard student t‑tests. 
Two‑way ANOVA analysis was used to determine the 
interaction between observed differences in APP/PS1 
mice and age.
Microarray analysis: GABAergic pathways 
In order to further strengthen our findings on 
the deficits in the GABA pathways in APP/PS1 mice, 
we focus on gene expression in the prefrontal cortex 
and hippocampus using microarrays. The brain tissue 
selection was based on the existing evidence on close 
involvement of these two brain areas in cognitive 
processes as found disturbed in the course of progressive 
AD pathology (DeKosky and Scheff 1990, Grady et al. 
2001, Mu and Gage 2011). At the pre‑specified age of 1.5 
and 8 months, brains from transgenic and wild‑type mice 
were removed immediately following decapitation and 
dissected on dry ice. For this specific microarray study, 
an additional group of 18 months old animals was added 
to provide a time point at which we have observed full 
blown seizure and seizure‑like events in this mouse 
model of AD (Oyelami et al. unpublished data). Tissue 
samples were obtained from the prefrontal cortex as well 
as the hippocampus from each mouse. After dissection all 
samples were stored at −80°C. 
Total RNA was prepared starting from tissue obtained 
from the hippocampus and prefrontal cortex (50–100 mg). 
Qiazol Lysis Reagent (Qiagen 79306) was added directly to 
each frozen brain tissue containing a Stainless steel bead 
with a diameter of 5 mm. Tissues were then disrupted 
and homogenized using the TissueLyser at maximum 
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speed for 5 min and chloroform was added. After phase 
separation by centrifugation and recovery of the aqueous 
phase, ethanol was added to provide appropriate binding 
conditions. Each sample was then applied to the wells of 
the RNeasy 96 RNeasy plate and washed according to the 
RNeasy 96 Universal Tissue procedure. RNA was eluted 
with 80 µl RNase free water (Eppendorf) OD260/280 and 
measured using the Nanodrop 8000 instrument.
All microarray‑related steps for target preparation, 
including the amplification of total RNA and labeling, 
were carried out as described in the GeneChip® HT 
3’ IVT PLUS Reagent Kit User Manual (Affymetrix 902417). 
In this protocol total RNA is reverse transcribed to 
synthesize first‑strand cDNA which is then converted 
into a double‑stranded DNA template for transcription. 
In vitro, further transcription of synthesized amplified 
RNA (aRNA) is performed and incorporated into 
biotin‑conjugated nucleotide. The aRNA is then purified 
to remove unincorporated NTPs, salts and enzymes using 
Agencourt RNA Clean beads. After fragmentation the 
biotin‑labeled target samples were hybridized to GeneChip 
HT HG‑MG430Array plates. Target hybridization, wash, 
stain and scan was processed according to the instructions 
provided in the Affymetrix® GeneTitan™ Instrument 
User’s Guide.
All microarray data were processed using R – the 
free software environment for statistical computing 
(R Development Core Team, 2006) as well as Bioconductor 
tools (Gentleman et al. 2004). The gene expression values 
were normalized using RMA (Irizarry et al. 2003). Grouping 
of the individual probes into gene‑specific probe set 
was based on Entrez Gene using the metadata package 
htmg430ammentrezg (Dai et al. 2005). For this study, we 
focus on the expression of interneuron specific genes i.e. 
glutamate decarboxylase 1 (Gad1), Cholecystokinin (CCK), 
Somatostatin (SST), Parvabulmin, Calretinin, Vasoactive 
intestine peptide (VIP); gamma‑aminobutyric acid solute 
carriers and receptors as well as association proteins. This 
resulted in a list of 40 genes of interest: Cck – Cckar – Cckbr 
– Gabarap – Gabarapl1 – Gabbr1 – Gabra1 – Gabra2 – Gabra3 – 
Gabra4 – Gabra5 – Gabra6 – Gabrb1 – Gabrb2 – Gabrb3 – Gabrd 
– Gabre – Gabrg1 – Gabrg2 – Gabrg3 – Gabrp – Gabrq – Gabrr1 – 
Gabrr2 – Gad1 – Gad1os – Gad2 – Gadl1 – Slc32a1 – Slc6a1 – Slc6a11 
– Slc6a12 – Slc6a13 – Sst – Sstr1 – Sstr2 – Sstr3 – Sstr4 – Sstr5 – Vip.
For these genes of specific interest, we compared APP/
PS1 mouse group with the littermate group at different 
ages (i.e. 1.5, 8 and 18 months) in the 2 brain regions of 
interest i.e. frontal cortex and hippocampus. At each age, 
expression levels are reported as log2 of the fold change 
between the transgenic and the littermate (logFC), average 
expression across both conditions and p values (corrected 
for multiple testing) for the differential expression between 
transgenic and littermates. The p values were computed 
using limma (Smyth 2004).
RESULTS
Electrophysiology: synaptic function and long‑term 
potentiation (LTP) 
At 1.5 months of age no statistically significant 
deficit was found in APP/PS1 mouse at the two time 
points of interest after induction of LTP (Figs 1A, 1C). 
However, we observed deficits in LTP at 8 months of 
age in APP/PS1 mouse as compared to littermates 
(Figs 1B, 1D). With induction of LTP, the slope of the 
fEPSP immediately after induction is increased to 
a ratio of 1.43±0.11 in littermates, which is significantly 
higher than the 1.16±0.04 increase observed in the APP/
PS1 mouse (t22=2.49, P<0.05). One hour after induction, 
magnitude of LTP induced in the littermates remained 
at 1.66±0.15 of normalized baseline, while in the APP/
PS1 mice it remained significantly lower at 1.22±0.08 
(t22=2.78, P<0.05) (Fig. 1D). Two‑way ANOVA, however, 
revealed no interaction between the age and genotype 
and/or recorded responses in the early and later stage 
of LTP. 
While no change was observed at 1.5 months of age, 
a lower response was recorded at 8 months in the IO 
curve obtained from APP/PS1 mice when compared to 
littermates (Fig. 2A, 2B). This reduction was found to be 
statistically significant at stimulation strengths 50µA 
(littermate=173±23 µV, APP/PS1=−109±10 µV; t83=2.60, 
P<0.05), 100 µA (littermate=−343±42 µV, APP/PS1=−202±22 
µV; t83=3.04, P<0.01) and 150 µA (littermate=−619±64 µV, 
APP/PS1=−397±42 µV; t73=2.92, P<0.01). Two‑way ANOVA 
revealed an interaction (F(6, 475)=2.33, P<0.05) between the 
different stimulation strength (F(6, 475)=101.4, P<0.0001) and 
age (F(1, 4754)=11.95, P<0.001) in APP/PS1 mice but not in 
littermates. 
Paired Pulse ratio (PPR), calculated as a ratio of the 
amplitude of the second to the first pulse at various 
inter‑pulse‑interval of stimulation, were observed to be 
significantly decreased in APP/PS1 mice at 8 months when 
compared to littermates, while no change is observed at 
1.5 months of age (Fig. 2C, 2D). The observed changes, 
at 8 months of age, are recorded at lower stimulation 
intervals (corresponding to higher frequency) of 0.02 s 
(littermate=1.04±0.02, APP/PS1=1.16±0.07; t48=2.10, P<0.05), 
0.05 s (littermate=1.32±0.03, APP/PS1=1.50±0.10; t48=2.32, 
P<0.05), 0.1 s (littermate=1.32±0.02, APP/PS1=1.48±0.08; 
t48=2.56, P<0.05) and 0.2 s (littermate=1.20±0.02, APP/
PS1=1.38±0.08; t48=2.97, P<0.01). When applying age as 
a factor of changes in inter‑stimulation interval, we 
observe an interaction (F(8, 522)=10.72, P<0.0001) between 
age (F(1, 522)=116.2, P<0.0001) in the littermates, i.e. higher 
PPR in the older littermates (F(8, 522)=78.99, P<0.0001) 
while this interaction is not significant in the APP/PS1 
cohort.
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Electrophysiology: GABA inhibitor application
At 1.5 months of age we observed no difference 
in the rise time of the population spike with 
the application of GABA inhibitors either in 
littermates and transgenic. However, when the 
same experiment was repeated at 8 months of age 
we observe statistical difference in the rise slope 
of the population spike in APP/PS1 mice compared 
to littermate. This is represented in the inset graph 
(Fig. 3) at two predetermined point, i.e. at 5 min 
(littermate=1.06±0.01 µV/ms, APP/PS1=1.45±0.06 µV/ms; 
t41=2.05, P<0.05) and 15 min (littermate=1.07±0.01 µV/ms, 
APP/PS1=2.04±0.14 µV/ms; t41=2.09, P<0.05) into the 
application of the GABA inhibitor cocktail. Two‑way 
ANOVA analysis revealed a significant difference in 
the interaction (F(3, 128)=2.762, P<0.05) with respect to 
genotype (F(3, 128)=2.86, P<0.05) and the application of 
the GABA inhibitors (F(1, 128)=3.915, P<0.05) at 15 min 
into application. No interaction was observed 
between the effect of GABA inhibitor application and 
age or genotype.
Electrophysiology: GABA agonist application
At 8 months of age we investigated the effect of 
diazepam on the paired pulse ratio in slices. We observed 
Fig. 1. LTP induction in APP/PS1 mouse model at 1.5 months and at 8 months of age. No significant difference is observed in the Long‑term potentiation 
(LTP) when induced with a high frequency stimulation protocol at 1.5 months in APP/PS1 mice (n=5 animals; 14 slices) in comparison to littermates (n=6 
animals; 17 slices) (see panels A and C). Using the same protocol, less LTP is recorded in APP/PS1 mice (n=5 animals; 13 slices) at 8 months of age when 
compared to age matched littermate (n=3 animals, 11 slices) (see panel B). Furthermore, at 8 months, statistical analysis shows deficits in the amount 
of LTP induced when normalized to baseline both at 1–10 min (littermates=1.43±0.11, APP/PS1=1.16±0.04; p<0.05) immediately after induction and at 
50–60 min after induction (littermates=1.66±0.15, APP/PS1=1.22±0.08; p<0.05) (see panel D). 
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a significant decrease in the paired pulse ratio in the 
littermate mouse with application of diazepam (PPR: 
baseline=0.74±0.0.03; diazepam application=0.64±0.03; 
percentage change=10.±0.05%; t30=2.38, P<0.05). This 
change was not significant in the APP/PS1 cohort (PPR: 
baseline=0.80±0.06; diazepam application=0.72±0.08; 
percentage change=7.3±0.05%). Using a 2‑way ANOVA 
we observed statistical significance based on genotype 
(F(1, 56)=6.22, P<0.05) and application of diazepam (F(1, 56)=8.93, 
P<0.01) but no interaction between the two.
Microarray analysis of GABAergic pathway
In the hippocampus, at 8 and 18 months of age, we observe 
decreased expression level of 3 of the 40 selected genes of 
interest (i.e. Cck, Sst and Vip), none of which is involved in the 
pathology of the APP/PS1 in the hippocampus at 1.5 months 
of age (Table I). The expression levels of both Sst and Vip 
were decreased by 8 months of age while Cck is only affected 
at a much later time point (18 months). In comparison to 
the limited transcriptional effects in the hippocampus, we 
Fig. 2. Synaptic function is significantly altered in APP/PS1 mouse at 8 months but not at 1.5 months of age. The synaptic function is altered in APP/PS1 
mice in comparison to littermates. Change in Input/Output (I/O) curve is not statistically significant at 1.5 months of age when comparing APP/PS1 cohort 
(n=5 animals; 14 slices) with age matched littermates (n=6 animals; 17 slices) (see panel A) similarly, no significant change was observed in the paired 
pulse ratio (PPR) at different frequencies of stimulation between APP/PS1 cohort and age matched littermates at this age (see panel B). When the same 
parameters are used, at 8 months of age we observed a  lower response in the I/O curve obtained from APP/PS1 mice (n=5 animals; 13 slices) when 
compared to littermates (n=3 animals; 11 slices) (see panel B). This reduction is statistically significant at stimulation strengths 50 µA (littermate=173±23, 
APP/PS1=−109±10; p<0.05) 100  µA (littermate=−343±42, APP/PS1=−202±22; p<0.01) and 150  µA (littermate=−619±64, APP/PS1=−397±42; p<0.01), The 
PPR in the APP/PS1 cohort (n=8 animals; 33 slices) increased in comparison the age‑matched littermate cohort (n=5 animals; 17 slices) when delivered at 
a frequency of 20–50 Hz (see panel D). 
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observe more transcriptional effects on these genes in the 
prefrontal cortex. Of the 40 genes of interest presented, 
17 were observed to be statistically significant at one or 
more time points when comparing the APP/PS1 cohort 
with littermates (Table II). While no changes were observed 
in the expression levels of GABA receptor types in the 
hippocampus, we observed decreases in the expression 
of the genes coding for different GABA receptors in the 
prefrontal cortex. These include changes in the Gabra1, 
Gabra3, Gabra4, Gabra5, Gabrb2, Gabrb3, Gabrg1 and Gabrg2 
gene transcription. Decrease was also observed in the 
GABA receptor associated protein Gabarapl1 while the level 
of Gabarap was increased. Finally, we observed exclusively 
in the prefrontal cortex decreases in the expression of the 
somatostatin receptors Sstr2 and Sstr3. 
Results obtained from the microarray data, confirms 
an involvement of the GABAergic system in the pathology 
observed in the APP/PS1 mouse especially in the prefrontal 
cortex. Additionally, the lack of changes in the GABA 
receptors expression in the hippocampus further explains 
Fig. 3. Alteration in the slope of population spike in APP/PS1 mouse at 8 months with application of GABA inhibitor compared to littermates. By applying 
a low concentration of bicucculine (5 µM) and 2‑hydroxysaclofen (20 µM) in slices obtained from APP/PS1 mouse at 1.5 months (APP/PS1: n=3 animals; 
12 slices and littermates: n=3 animals; 13 slices) and 8 months (APP/PS1: n=6 animals; 17 slices and littermates: n=9 animals; 23 slices) we were able to 
monitor the age‑dependent involvement of the GABA pathway in the pathology of APP/PS1 mice compared to littermates. No changes were observed 
in between the littermate and transgenic group at 1.5 months of age. However, an increase in the decay slope of the population spike is observed at 
8 months of age (see panel A). Example traces from baseline and during application of the GABA antagonists in sample slice recorded from a littermate 
mouse and APP/PS1 mouse are provided (see panels B and C). The analysis of the changes in paired pulse depression in slices with application of 
benzodiazepine, a γ‑aminobutyric acid receptor A (GABAA) agonist, at 8 months in APP/PS1 (n=6 animals; 12 slices) mouse cohort showed no statistical 
significance when compared to littermates (n=5 animals; 16 slices) (see panel D). 
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why we were unable to obtain immunohistochemistry 
difference in the hippocampus of this mouse model at 
8 months of age. 
DISCUSSION
Although all evidence from electrophysiological 
observations, such as a decrease in the input/output curve 
and a reduction in the probability of release, point to 
a decreased synaptic response in the APP/PS1 mouse, it is 
generally accepted that the observed synaptic depression 
is not sufficient in explaining all of the pathology observed 
in AD (Palop et al. 2007, Palop and Mucke 2009, 2010). 
Various mutations in the APP protein and over‑production 
of the protein itself have both been shown to lead to an 
increase in seizure susceptibility in patients and in AD 
models (Palop et al. 2007, Irizarry et al. 2012). In a similar 
vein, the PS1 protein mutations and specifically mutations 
in the Leucine 166 also present in the specific mouse 
model used in this study have also been shown to result 
in an increase in the susceptibility to seizures (Rossor 
et al. 1996, Mann et al. 2001, Moehlmann et al. 2002). 
In the clinical setting, AD patients have been shown to 
exhibit seizures or seizure‑like activity, indicative of an 
an increase in excitability that seemingly contradicts the 
well‑documented synaptic depression in the mouse models 
as well as in AD patients (Amatniek et al. 2006, Minkeviciene 
et al. 2009, Palop and Mucke 2009). While the glutamatergic 
pathway is established to be deficit in the disease state, 
the documented alterations in the glutamatergic pathway 
alone fails to explain the synaptic depression in AD coupled 
with hyperexcitability (Hoxha et al. 2012).
Taken together the synaptic depression and 
hyperexcitability observed in the disease pathology, 
it has been hypothesized that the changes in the 
function of the excitatory glutamate pathway may be 
causally, related to or at least correlated with changes 
in the counterbalancing GABAergic inhibitory pathway 
(Amatniek et al. 2006, Minkeviciene et al. 2009, Verret 
et al. 2012, Hazra et al. 2013). Moreover, the preferential 
susceptibility of interneurons to Aβ toxicity has been 
previously documented (Davies et al. 1980, Ramos et al. 
2006, Takahashi et al. 2010, Verret et al. 2012).
The present study found that synaptic depression 
resulting in LTP deficits and decreased response during 
stimulation in the APP/PS1 mouse was observed at 
8 months, but not at 1.5 months. This finding confirms 
that the neuronal and functional pathology in the APP/
PS1 mouse is age/pathology related (Trinchese et al. 2004). 
Increase in the short‑term plasticity which corresponds to 
a reduced probability of release of neurotransmitters in 
the APP/PS1 mouse is observed at an older age of 8 months 
but not at 1.5 months: also in line with the progressive and 
pathology‑related deficits in the functioning of the brain in 
AD. Previous studies have indeed reported that the altered 
synaptic plasticity known to occur in AD mouse models are 
in fact age/pathology dependent (Bergado and Almaguer 
2002, Fitzjohn et al. 2010, Gengler et al. 2010). We report 
here specific changes that are statistically linked to the 
age/pathology in the APP/PS1 mouse model. Similar to the 
observed synaptic depression, the susceptibility to seizures 
in AD patients as well as in mouse models is increased 
with the progression of the pathology of the disease 
(Hauser et al. 1986, Amatniek et al. 2006, Cloyd et al. 2006). 
It is therefore reasonable to assume that changes in the 
GABAergic pathway are also subjected to the progressive 
pathology of AD. 
In the second set of experiments conducted, we observed 
changes in the synaptic response with the blockade of the 
GABA pathway, i.e. an increased excitability of slices that 
is consistent with an increase in the seizure susceptibility/
hyperexcitability observed in previous studies (Davies et 
al. 1980, Minkeviciene et al. 2009, Hoxha et al. 2012). The 
concomitant involvement of the GABAergic system and 
synaptic depression in AD pathology is further strengthened 
Table I. Differential expression of GABA related genes in the hippocampus of APP/PS1 mice compared to littermate over 3 time points as observed by 
microarray based expression profiling
Hippocampus GABA related genes 1.5 months 8 months 18 months
Symbol Genename logFC Ave Expr adj. P.Val logFC Ave Expr adj. P.Val logFC Ave Expr adj. P.Val
Sst somatostatin −0.23 9.83   −0.38 9.88 * −0.80 9.71 ***
Vip vasoactive intestinal  polypeptide −0.01 7.80   −0.37 7.66 * −0.35 7.65  
Cck cholecystokinin 0.04 11.02   −0.13 10.91   −0.29 10.81 **
The time points studied are 1.5 months (littermate: n=8, APP/PS1: n=8), 8 months (littermate: n=8, APP/PS1: n=8), and 18 months (littermate: n=5, APP/PS1: n=6). The represented 
genes have been selected from a list of 40 genes of potential interest being of relevance to the γ‑aminobutyric acid pathway (GABAergic). The listed genes are significant at 
one or more of the three time points. These include genes encoding for γ‑aminobutyric acid (GABA) receptors, solute carriers and associated proteins. For each gene and at 
each time point, the log2 fold change (logFC), the mean expression across groups (AveExpr) and the p value for differential expression after correcting for multiple testing 
(adj.P.Val) are reported. The genes are ordered based on increasing p values at 8 months of age, followed by 18 months and finally at 1.5 months of age. Non‑significant genes 
are excluded from the table. We observe very little change in the hippocampal expression of the selected genes. The observed differences were restricted to the interneuron 
related/specific genes Vip, Sst and Cck. No significant change was observed at 1.5 months of age.
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Table II. Differential expression of GABA related genes in the prefrontal cortex of APP/PS1 mice compared to littermate over 3 time points as observed by 
microarray based expression profiling
Prefrontal cortex GABA related genes 1.5 months 8 months 18 months
Symbol Genename logFC Ave Expr adj. P.Val logFC Ave Expr adj. P.Val logFC Ave Expr adj. P.Val
Cck cholecystokinin 0.11 11.53   −0.33 11.21 *** −0.12 11.27  
Gabrb2
gamma‑aminobutyric 
acid (GABA) A 
receptor, subunit 
beta 2
0.10 9.60   −0.32 9.44 *** −0.27 9.54 ***
Sstr2 somatostatin receptor 2 −0.04 6.68   −0.82 6.35 *** −0.44 6.59  
Gabrb3
gamma‑aminobutyric 
acid (GABA) A 
receptor, subunit 
beta 3
0.08 8.04   −0.31 7.88 *** −0.25 7.86 *
Gabarapl1
gamma‑aminobutyric 
acid (GABA) A 
receptor‑associated 
protein‑like 1
0.01 10.56   −0.24 10.57 *** −0.07 10.67  
Gabra1
gamma‑aminobutyric 
acid (GABA) A 
receptor, subunit 
alpha 1
0.14 9.91   −0.42 9.81 *** −0.28 10.02  
Sst somatostatin −0.01 9.95   −0.49 9.55 *** −0.63 9.74 ***
Gabrg2
gamma‑aminobutyric 
acid (GABA) A 
receptor, subunit 
gamma 2
0.11 8.70   −0.41 8.48 *** −0.27 8.70  
Gabra5
gamma‑aminobutyric 
acid (GABA) A 
receptor, subunit 
alpha 5
−0.07 7.49   −0.33 7.37 *** −0.29 7.31 *
Gabra3
gamma‑aminobutyric 
acid (GABA) A 
receptor, subunit 
alpha 3
0.12 8.22   −0.40 8.12 *** −0.18 8.23  
Gabra4
gamma‑aminobutyric 
acid (GABA) A 
receptor, subunit 
alpha 4
0.18 8.82   −0.25 8.48 ** −0.19 8.61  





0.03 9.61   0.17 9.77 * 0.21 9.78  
Cckbr cholecystokinin B receptor 0.12 7.38   −0.32 7.27 * 0.01 7.29  
Slc32a1
solute carrier family 
32 (GABA vesicular 
transporter), 
member 1
−0.19 7.56   −0.18 7.62   −0.36 7.45 *
Gabrg1
gamma‑aminobutyric 
acid (GABA) A 
receptor, subunit 
gamma 1
−0.21 6.12   0.06 6.23   −0.38 5.94 *
Slc6a11




−0.55 6.87 * 0.23 7.25   −0.12 6.87  
The time points studied are 1.5 months (littermate: n=8, APP/PS1: n=8), 8 months (littermate: n=8, APP/PS1: n=8), and 18 months (littermate: n=5, APP/PS1: n=6). The represented 
genes have been selected from a list of 40 genes of potential interest being of relevance to the γ‑aminobutyric acid pathway (GABAergic). The listed genes are significant at 
one or more of the three time points. These include genes encoding for γ‑aminobutyric acid (GABA) receptors, solute carriers and associated proteins. For each gene and at 
each time point, the log2 fold change (logFC), the mean expression across groups (AveExpr) and the p value for differential expression after correcting for multiple testing 
(adj.P.Val) are reported. The genes are ordered based on increasing p values at 8 months of age, followed by 18 months and finally at 1.5 months of age. Non‑significant genes 
are excluded from the table. We observe changes in several receptor subunits (Gabra1, Gabarap, Gabara3, Gabara4, Gabara5, Gabrb2, Gabrb3, Gabrg1 and Gabrg2and Gabrg2); 
interneuron specific/related genes (Cck, Cckbr, Sst, Sstr2 and Sstr3) and in the solute carrier for the GABA amino acid (Slc6a11). Almost all of these changes are recorded in the 8 
and 18 months cohort while only the Slc6a11 gene is significantly decreased at 1.5 months of age.
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by previous study showing that manipulation of the 
GABAergic/inhibitory system can rescue LTP and memory 
deficiency in APP/PS1 mouse model (Meilandt et al. 2008, 
Yoshiike et al. 2008, Andrews‑Zwilling et al. 2010, Tong et al. 
2014). Our results confirm this finding, and in addition show 
that the involvement of the GABAergic system is restricted 
to a later point in the pathological progression of the disease 
(i.e. at 8 months and not at 1.5 months). 
The present results concur with findings of studies that 
support an involvement of the GABAergic pathway in the 
pathology (synaptic depression) of the APP/PS1 mouse 
model (Yoshiike et al. 2008, Palop and Mucke 2009, Hoxha 
et al. 2012, Jo et al. 2014). Two possible hypotheses may aid 
in the interpretation of the results we obtained with the 
blockade of the GABAergic pathway: the first hypothesis 
would view the results in terms of a decreased GABAergic 
pathway innervation and function that is irrespective 
of possible changes in excitation. A second possible 
hypothesis and alternative interpretation is that there is 
an increased GABA pathway innervation/function with no 
change in the excitation.
The involvement of the glutamatergic pathway in the 
pathology of AD has previously been documented based 
on changes in the distribution of the different glutamate 
receptor types and also evident by the fact that Memantine, 
a NMDA agonist remains one the most successful 
symptomatic treatment for AD (Nankai et al. 1995, Blumcke 
et al. 1996, Winblad and Poritis 1999, Shankar et al. 2007). 
Thereby justifying the dismissal of the second hypothesis 
proposed above that the glutamatergic/excitatory 
pathway is unchanged. In fact, a partial augmentation of 
the GABAergic system by application of diazepam shows 
a trend towards a decreased functionality of the GABAA 
receptor at 8 months of age. In order to further confirm the 
first hypothesis on a decreased GABA pathway function, we 
studied the results obtained from the microarray analysis 
of GABAergic pathway‑related genes. Previous research has 
established the loss of different interneurons or a reduction 
in the function of such interneurons in AD (Takahashi et 
al. 2010). Compared to the observed gene changes in the 
hippocampus, results from the microarray analysis show 
more differentially expressed genes in the prefrontal cortex 
of APP/PS1 mice as compared to the littermates. This hints 
towards a preferential involvement of the prefrontal cortex 
specifically in the changes observed in the GABAergic 
pathway in AD (Davies et al. 1980, Howell et al. 2000, Harris et 
al. 2010). In the hippocampus, GABAergic gene changes were 
restricted to decreases for 3 different interneuron markers, 
i.e. Cck, important for mood disorder and anxiety, Vip and Sst 
(Davies et al. 1980, Freund and Katona 2007). In the prefrontal 
cortex, the observed gene changes include decreases in 
different GABA receptor subunits and associating proteins, 
some of which have been previously reported (Yoshiike et al. 
2008, Limon et al. 2012, Schwab et al. 2013). 
Focusing on the differences in expression observed 
in the prefrontal cortex for the GABAergic genes, it is 
clear that the greatest effects are observed at the age 
of 8 months. This finding supports the age‑dependent/
disease progression as key factors in GABA pathology. At 
1.5 months, only 1 of the 40 GABAergic genes is affected, i.e. 
Slc6a11, encoding for Gat3, a GABA transporter, expressed 
in astrocytes (Durkin et al. 1995, Borden 1996). Gat3 is an 
important tonic modulator for GABAergic signaling in the 
hippocampus (Borden 1996, Kersante et al. 2013, Schwab 
et al. 2013). Thus, while at least this one change can be 
found at 1.5 months of age, majority of the changes in the 
pathway seem to occur at a later time point of the disease 
progression. 
At the age of 8 months, the number of significantly 
affected GABAergic genes is higher than at the 2 other 
time points studied. Most, but not all, of the affected 
genes are in fact down regulated in the mutant mice. 
Overall, the decrease in the expression of GABA related 
genes indicates a decrease in the efficiency of the GABA 
pathway. This study further shows that these changes 
occur concomitantly with previously documented 
changes in the glutamatergic pathway.
From our findings, we report that APP/PS1 mouse 
model present deficits in synaptic function, some of 
which are affected with age. In addition, functional and 
transcriptional deficits were observed in the GABAergic 
pathways. These documented synaptic dysfunction 
in AD models is increased with age and concomitantly 
observed with excitation/inhibition imbalance therefore 
suggesting underlying evidence for observation of 
symptoms such as sleep disturbances, seizures and 
seizure‑like effects observed in AD pathology (Amatniek 
et al. 2006, Palop et al. 2007, Palop and Mucke 2009, 
Irizarry et al. 2012). 
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